Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347340 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL12196590 | 0.96 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL10013951 | 0.96 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL3102269 | 0.96 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL12196447 | 0.96 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL12196445 | 0.96 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL12196461 | 0.96 | SLC10A2 (0.93) | SLC10A2 | |
| SCHEMBL14904726 | 0.89 | SLC10A2 (0.88) | SLC10A2 | |
| SCHEMBL3089112 | 0.88 | SLC10A2 (0.82) | SLC10A2 | |
| Trimethylammonium SCHEMBL27609174 | 0.88 | SLC10A2 (0.80) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020167958-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-8106023-B2 | 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-8106023-B2 | 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20100035834-A1 | NOVEL 1,4-BENZOTHIEPIN-1, 1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS DEUTUSCHLAND GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035834-A1 | NOVEL 1,4-BENZOTHIEPIN-1, 1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS DEUTUSCHLAND GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035834-A1 | NOVEL 1,4-BENZOTHIEPIN-1, 1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | PTGS1, TBXAS1, SULT1E1 | SLC10A2 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.